Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471865 | 0.78 | QPCT (0.39) | LRRK2KMT2A | |
| SCHEMBL9918974 | 0.77 | LMNA (0.38) | LMNAHTTRECQLKMT2APDE10A | |
| SCHEMBL2817366 | 0.77 | ALDH1A1 (0.43) | HTTLRRK2KMT2A | |
| SCHEMBL1180511 | 0.77 | NUDT1 (0.44) | P2RX3P2RX2HTTKMT2A | |
| SCHEMBL10304905 | 0.76 | KMT2A (0.52) | P2RX3P2RX2LMNARECQLKMT2A | |
| SCHEMBL9977648 | 0.74 | LMNA (0.36) | LMNAHTTRECQLKMT2APDE10A | |
| SCHEMBL31366250 | 0.74 | GAA (0.40) | P2RX3P2RX2LMNAHTTRECQL | |
| SCHEMBL12093317 | 0.74 | LRRK2 (0.39) | LMNAHTTLRRK2KMT2APDE10A | |
| SCHEMBL13004012 | 0.74 | GAA (0.40) | P2RX3P2RX2LMNAHTTRECQL | |
| SCHEMBL10216223 | 0.72 | P2RX3 (0.42) | P2RX3P2RX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197962-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | P2RX3 3481/4885P2RX2 3241/4885LMNA 2843/4885 |
| US-20170253594-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | P2RX3 3481/4885P2RX2 3241/4885LMNA 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.